Pulsenmore Expands Its Fertility Platform into the UK

Pulsenmore (NASDAQ: PLSM, TASE: PLSM) has expanded its fertility platform into the UK after completing MHRA registration for its home ultrasound system, Pulsenmore FC. The system allows women undergoing IVF to perform vaginal ultrasound scans at home, reducing clinic visits. The UK market saw over 100,000 fertility treatment cycles in 2024, according to the HFEA.

Original reporting
Published Sep 17, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 11:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$PLSM
Bullish
medium confidence
Mentioned
$PLSM
Relevance
7/10
AlphAI data visualization · based on morningstar.com
Decision brief

The 30-second read

$PLSMBullishMed
01

Why it matters

The MHRA registration enables the company to market its fertility platform in the UK, expanding its addressable market beyond Europe.

02

Market read

Regulatory clearance could drive near‑term stock appreciation as the UK fertility market is sizable.

03

What to watch

The company still needs to build distribution channels and secure insurance coverage in the UK.

Relevance 7/10Novelty 8/10Timing: today

Background

Pulsenmore, a Nasdaq‑listed healthcare‑tech company, develops self‑use ultrasound devices for remote care.

Company-level read

Ticker impact

$PLSMBullishMedium confidence
Context

Pulsenmore received MHRA registration for its Pulsenmore FC, allowing sales in the UK and Northern Ireland.

Expected impact

Potential upside as investors price in UK market expansion.

Evidence & confidence

First-time UK approval for a niche home‑ultrasound product; market size is sizable but execution risk remains.

Market effects

Highlights growth potential for remote‑diagnostic and women's health tech firms.

Adds competitive pressure on UK fertility service providers.

Signals broader acceptance of home‑ultrasound solutions in regulated markets.

Counterpoint

UK entry may be slower than expected due to reimbursement hurdles and clinician adoption.

Key entities

  • Pulsenmore Ltd.

    NASDAQ: PLSM, developer of remote ultrasound solutions.

  • MHRA

    UK Medicines and Healthcare products Regulatory Agency.

Related articles

$PLSMMed

Pulsenmore Ltd.: Pulsenmore Expands Its Fertility Platform into the UK

Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM) has registered its home ultrasound system, Pulsenmore FC, with the UK's MHRA, allowing it to market the product in the UK and Northern Ireland. The system is designed for women undergoing IVF and fertility preservation treatments, enabling at-home monitoring. The UK fertility market saw over 100,000 treatment cycles in 2024, according to the HFEA. This expansion follows the company's recent European registration under the Medical Device Regulation (MDR

$PLSMMed

Pulsenmore Ltd. (PLSM): Financial results for H1 2026

Pulsenmore Ltd. (PLSM) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 Pulsenmore Ltd. Announces Financial Results and Business Highlights for the First Half of 2026 Management to Host Webcast today at 8:30 am ET to discuss Results and Provide Business Update Omer, Israel –August 31, 2026 – Pulsenmore Ltd. (Nasdaq/TASE: PLSM ), a leadin

$PLSMMed

Pulsenmore stock surges 160% on Israel AI program selection By Investing.com

Pulsenmore Ltd. (NASDAQ:PLSM) shares jumped about 160% after the company said it was selected for Israel’s Healthcare AI Regulatory Sandbox Program by the Israel Innovation Authority and Ministry of Health. Pulsenmore will receive funding for a $1 million project to develop and clinically validate AI for its home ultrasound platform, with Beilinson Hospital/Clalit Health Services.

$METAMed

OpenAI, Google, Anthropic hit with lawsuit seeking halt to frontier AI development

Nonprofits sued OpenAI, Anthropic, SpaceX’s AI division, Meta, and Google in San Francisco, seeking to halt development of advanced AI models like ChatGPT, Gemini, and Claude. The lawsuit cites concerns from company leaders about AI's potential risks and past incidents. Meta declined to comment, while other companies did not immediately respond. Separately, Florida and eight other states have filed lawsuits against OpenAI over similar concerns.

$BABAHigh

Alibaba shares slide 7% as Nvidia crisis and US chip curbs threaten AI ambitions

Alibaba (BABA) shares dropped 7% to $94.77 amid reports of stricter US restrictions on Chinese firms accessing advanced AI chips. The US Commerce Department may block remote access to processors, affecting Alibaba's cloud computing plans. Alibaba's ties to Nvidia partner Megaspeed, linked to Chinese intelligence, also raised concerns. Nvidia's CEO resigned over the controversy. Alibaba reports Q3 earnings on November 19, with its T-Head semiconductor unit planned for a Hong Kong IPO.

$NVDAMed

Nvidia Investigation Widens: DOJ Probes, SMCI Falls 11%

Nvidia faces multiple investigations from the DOJ and Congress, with shares down 5.2% and Super Micro Computer falling 11.6%. Probes focus on potential legal risks in the supply chain, not directly on Nvidia. CEO Jensen Huang's resignation may impact shareholder claims. Nvidia's interim chief will address staff before Q3 results on 17 November.